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Tungsten has been used for many years in a
variety of applications. Combining the hard,
brittle tungsten metal with various other met-
als, including nickel and cobalt, produces
tungsten alloys (WAs) with speciﬁc character-
istics, some of which are of interest to the
military. Recently, WAs have replaced lead in
some small-caliber ammunition (the “green
bullet”) [Oak Ridge National Laboratory
(ORNL) 1998] and depleted uranium (DU)
in kinetic-energy penetrators (ORNL 1996).
Based on a small number of studies, prevail-
ing theory is that elemental tungsten or
insoluble tungsten compounds have only lim-
ited toxicity (Leggett 1997). For example,
tungsten coils implanted into the subclavian
artery of rabbits rapidly degrade, leading to
elevated serum tungsten levels as early as
15 min after implantation. However, after
4 months, no signs of local or systemic toxic-
ity were observed (Peuster et al. 2003).
Studies on health effects of Ni and Co are
more numerous. Intramuscular injections
(28 mg) of soluble metallic Ni or Co result in
formation of rhabdomyosarcomas at the
injection site. With Ni, 100% of injected rats
develop a tumor within 41 weeks (Heath and
Daniel 1964), whereas administration of Co
results in tumor formation in 40% of the rats
with a latency period of 71 weeks (Heath
1954, 1956). However, intramuscular
implantation of rods or pellets composed of
various Ni or Co alloys used in orthopedic
prosthetics results in no excessive tumor for-
mation (Gaechter et al. 1977; Sunderman
1989). A variety of other Ni compounds,
including nickel subsulﬁde, nickel oxide, and
nickel monosulﬁde, have been tested for car-
cinogenic potential via intramuscular admin-
istration (Gilman 1962; Sunderman and
Maenza 1976; Sunderman et al. 1977).
Tumors (rhabdomyosarcoma and fibrosar-
coma) were found in many cases at the injec-
tion site, with tumor yield dependent on
solubility and concentration of the adminis-
tered compound. It has been postulated that
the yield of localized tumors is inversely
related to the rate of solubilization of the Ni-
containing compound (Kasprzak et al. 1983).
This hypothesis does not appear to hold for
Co compounds (Lison et al. 2001).
Metal alloys present additional problems
when investigating health effects. The various
metals comprising the alloy, as well as the
method of production, can all factor into the
overall health effect observed upon exposure.
Investigations on hard-metal disease have
shown that either tungsten carbide or Co
alone has limited toxicity on lung tissue
(Lasfargues et al. 1992). However, when
combined, the tungsten carbide/cobalt mix-
ture acts synergistically to increase the
observed toxicity. It is not known whether
this is due to the combined toxicity of the
tungsten carbide/cobalt mixture or to an
increase in the bioavailability of the known
toxicant, Co (Lison and Lauwerys 1997).
In vitro studies investigating malignant trans-
formation of immortalized human cells by
mixtures of tungsten, Ni, and Co suggest a
synergistic effect that greatly exceeds the
effects of the metals individually (Miller et al.
2001, 2002).
Advancements in metallurgy have led the
military of many nations to replace DU in
some armor-penetrating munitions and lead
in small-caliber ammunition with various
alloys of tungsten. One motivation for such a
replacement is widespread public concern
about the health and environmental impact of
continued use of these metals. However, to
our knowledge, none of these militarily rele-
vant WAs has been tested for potential health
effects, especially as embedded shrapnel.
There is a growing list of health concerns
related to tungsten exposure. Although a
deﬁnitive link has not been established, several
cancer clusters in the United States are associ-
ated with elevated levels of tungsten in the
environment. Those ﬁndings, along with the
results presented in this article, raise questions
about the possible consequences of tungsten
exposure. More important, these results raise
extremely serious concerns over the potential
health effects of WA-based munitions cur-
rently being used as nontoxic alternatives to
lead and DU.
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Continuing concern regarding the potential health and environmental effects of depleted uranium
and lead has resulted in many countries adding tungsten alloy (WA)-based munitions to their
battleﬁeld arsenals as replacements for these metals. Because the alloys used in many munitions are
relatively recent additions to the list of militarily relevant metals, very little is known about the
health effects of these metals after internalization as embedded shrapnel. Previous work in this labo-
ratory developed a rodent model system that mimicked shrapnel loads seen in wounded personnel
from the 1991 Persian Gulf War. In the present study, we used that system and male F344 rats,
implanted intramuscularly with pellets (1 mm × 2 mm cylinders) of weapons-grade WA, to simu-
late shrapnel wounds. Rats were implanted with 4 (low dose) or 20 pellets (high dose) of WA.
Tantalum (20 pellets) and nickel (20 pellets) served as negative and positive controls, respectively.
The high-dose WA-implanted rats (n = 46) developed extremely aggressive tumors surrounding
the pellets within 4–5 months after implantation. The low-dose WA-implanted rats (n = 46) and
nickel-implanted rats (n = 36) also developed tumors surrounding the pellets but at a slower rate.
Rats implanted with tantalum (n = 46), an inert control metal, did not develop tumors. Tumor
yield was 100% in both the low- and high-dose WA groups. The tumors, characterized as high-
grade pleomorphic rhabdomyosarcomas by histopathology and immunohistochemical examina-
tion, rapidly metastasized to the lung and necessitated euthanasia of the animal. Significant
hematologic changes, indicative of polycythemia, were also observed in the high-dose WA-
implanted rats. These changes were apparent as early as 1 month postimplantation in the high-
dose WA rats, well before any overt signs of tumor development. These results point out the need
for further studies investigating the health effects of tungsten and tungsten-based alloys.
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[Online 15 February 2005]Materials and Methods
Rodents. Male F344 rats (6 weeks of age;
Harlan, Frederick, MD) were maintained in a
facility accredited by the Association of
Assessment and Accreditation of Laboratory
Animal Care in accordance with the Guide for
the Care and Use of Laboratory Animals
(Institute of Laboratory Animal Resources
1996). All procedures, including euthanasia
criteria (Tomasovic et al. 1988), were
approved by the Armed Forces Radiobiology
Research Institute’s (AFRRI) Animal Care
and Use Committee. Upon arrival, animals
were screened for common rodent pathogens.
Rats were pair-housed in plastic microisolator
cages with hardwood chips for bedding and
fed a certified NTP-2000 (Quality Lab
Products, Elkridge, MD) diet (Rao 1996)
with acidified water provided ad libitum.
Animals were on a 12-hr light/dark cycle with
no twilight and were weighed weekly.
Pellets. All metal pellets were cylinders
1 mm in diameter and 2 mm in length.
Nickel (99.995% metallic Ni) and tantalum
(99.95% Ta) pellets were purchased from
Alfa Aesar (Ward Hill, MA). WA pellets were
fabricated by Aerojet Ordnance Tennessee
(Jonesborough, TN) using standard kinetic
energy penetrator production processes. An
average WA pellet weighed 27.5 mg and con-
sisted of 91.1% tungsten, 6.0% Ni, and 2.9%
Co. Ni and Ta pellets weighed 14 mg and
27 mg, respectively. Before implantation
surgery, all pellets were cleaned and chemi-
cally sterilized (Pellmar et al. 1999).
Pellet-implantation surgery. A rodent
model system (AFRRI 1996), originally
developed to mimic DU shrapnel loads seen
in wounded personnel from the 1991 Persian
Gulf War, was used to investigate the health
effects of retained WA shrapnel. All rats were
implanted with a total of 20 pellets split
evenly between each hind leg. Experimental
groups included Ta (negative control, 20 Ta
pellets), low-dose WA (4 WA pellets and
16 Ta pellets), high-dose WA (20 WA pel-
lets), and Ni (positive control, 20 Ni pellets).
Tantalum was used as a negative implantation
control because it is considered inert and has
been used in human prostheses (Hockley
et al. 1990; Johansson et al. 1990). Nickel, a
known carcinogen, was used as a positive con-
trol (Costa and Klein 1999; Kasprzak et al.
2003). Rats were implanted at 9 weeks of age.
For the pellet implantation procedure, anes-
thesia was induced by continuous administra-
tion of isoﬂurane using an open circuit system
with a scavenger/recapture system. All surgery
was done using aseptic techniques. After the
surgical sites were clipped and cleansed with
Betadine, an incision was made through the
skin to expose the gastrocnemius muscle.
Pellets were implanted in the muscle, spaced
approximately 1.5 mm apart on the lateral
side of each leg. The incision was closed with
sutures and tissue adhesive. Rats were closely
monitored after surgery until they were
ambulatory. An analgesic (buprenorphine
hydrochloride; Reckitt and Colman, Hull,
UK) was administered preoperatively and
then as needed postoperatively. The surgical
sites were examined daily for signs of inﬂam-
mation, infection, and local metal toxicity.
Experimental groups. Our pellet implanta-
tion groups included Ta (negative control),
WA (both a low- and high-dose group), and
Ni (positive control). The original euthanasia
time points were to be 1, 3, 6, 12, 18, and
24 months; however, because of the rapid
tumor development, no WA- or Ni-implanted
rat survived much past 6 months post-
implantation. Final survival data therefore
included rats originally assigned to the 12-,
18-, and 24-month experimental groups,
whose animals died earlier than those desig-
nated time points. This resulted in group sizes
of n = 46 for the Ta and both WA groups, and
n = 36 for the Ni group. Hematologic assess-
ments were conducted on the separate 1-, 3-,
and 6-month WA implantation groups.
Pathology. At various times postimplanta-
tion or when moribund, rats were euthanized
by isoflurane overdose. A complete gross
pathology examination was conducted, noting
any abnormalities, and tissues were collected
for analysis. Weights of representative tissues,
including spleen, thymus, testes, kidney, and
liver, were determined and normalized to
body weight. Tissues for histopathology were
fixed in buffered formalin, processed and
embedded in paraffin, cut at 5–6 µm,
mounted, and stained with hematoxylin and
eosin (H&E). Immunohistochemical analysis
was conducted on 5-µm-thick sections of for-
malin-ﬁxed, parafﬁnized tissue. After deparaf-
ﬁnation and rehydration, nonspeciﬁc binding
was blocked with Power Block (Biogenex, San
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Figure 1. Survival times of pellet-implanted rats.
Figure 2. Effect of implanted WA pellets on F344 rats. (A) Gross appearance of Ta-implanted hind leg.
(B) Dissected area around implanted Ta pellet (arrow indicates pellet). (C) Gross appearance of WA-
implanted hind leg with tumor(s). (D) Dissected area around implanted WA pellet with tumor surrounding
pellet (arrow indicates pellet). Bar = 2 cm.Ramon, CA). The tissue was then reacted with
prediluted rabbit anti-desmin polyclonal anti-
body (Biogenex) and treated with biotinylated
secondary anti-rabbit antibody (Biogenex).
After blocking with hydrogen peroxide, the
tissue sections were labeled with peroxidase-
conjugated streptavidin (Biogenex) and
aminoethyl carbazole (AEC; Biogenex) was
used as a chromogen. Slides were then counter-
stained with hematoxylin and mounted.
Hematology. At euthanasia, we obtained
blood for hematologic assessments from the
abdominal aorta of isoflurane-anesthetized
rats using a heparinized needle and sample
tubes containing EDTA (Becton-Dickinson,
Franklin Lakes, NJ). We determined white
and red blood cell counts; hemoglobin;
hematocrit; mean corpuscular volume, hemo-
globin, and hemoglobin concentration; red
cell distribution width; platelet counts and
volume; and neutrophil, lymphocyte, mono-
cyte, eosinophil, and basophil counts with a
Bayer Advia 120 Hematology Analyzer (Bayer
Diagnostics, Terrytown, NY).
Results
All rats tolerated the pellet implantation pro-
cedure with no apparent adverse effects. The
incision sites were examined daily; no rat
showed any signs of infection from the
surgery, or any discomfort postoperatively.
Body weights were recorded weekly. Once
they had recovered from the surgical proce-
dure, all rats gained weight at equivalent rates.
However, in the first week after the pellet
implantation surgery, the rate of weight gain
by the Ta and low-dose WA rats was slower
than normal, and high-dose WA and Ni rats
lost weight. This was followed by large weight
gains in postimplantation week 2 in all exper-
imental groups. There were no statistical dif-
ferences in rate of body weight gain between
any of the groups throughout the remaining
experimental period. As previously reported,
the implantation and retention of cylindrical
metal pellets (1 mm × 2 mm) had no effect
on locomotive abilities in rats (AFRRI 1996;
Pellmar et al. 1999), nor did we observe any
such difﬁculties in this study.
At approximately 16–20 weeks post-
implantation, we began to observe tumors at
the pellet implantation sites in the WA and Ni
rats. In some high-dose WA animals, palpable
tumors were apparent as early as 14 weeks
postimplantation. Tumors developed rapidly
in WA-implanted animals. The tumors were
aggressive and fast growing, necessitating
euthanasia of the animals several weeks later.
On the basis of previously published literature
(Heath and Daniel 1964), we expected the
Ni-implanted positive control rats to develop
tumors at the implantation site, but the speed
at which the tumors developed was surprising:
approximately 5 months after implantation.
Figure 1 shows the percentage of surviving
animals as a function of time after pellet
implantation. Rats implanted with Ta pellets
(n = 46) survived well beyond 12 months with
no apparent health problems. All rats in the
high- and low-WA and the Ni groups devel-
oped tumors and were euthanized upon
becoming moribund. Rats in the high-dose
WA group (n = 46) survived the least amount
of time (mean survival time ± SD = 21.8 ±
2.1 weeks). Nickel-implanted animals (n = 36)
and the low-dose WA group (n = 46) survived
slightly longer, with mean (± SD) survival
times of 25.4 ± 2.1 and 27.0 ± 4.6 weeks,
respectively. The mean survival time of the
high-dose WA animals was significantly
shorter than that of the low-dose WA- or Ni-
implanted animals [analysis of variance
(ANOVA) followed by Dunnett’s test,
p < 0.05]. The mean survival times of the low-
dose WA- and the Ni-implanted animals were
not statistically different from each other. The
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Figure 3. Histopathologic examination of leg tumor surrounding WA pellet. (A) H&E-stained section of leg
tumor from F344 rat showing WA pellet hole (P); bar = 500 µm. (B) H&E-stained tumor section showing neo-
plastic inﬁltration of preexisting muscle ﬁbers (MF); bar = 200 µm. (C) H&E-stained tumor section showing
neoplastic cells with numerous mitoses (arrows) and bizarre mitotic ﬁgures (BZ); bar = 100 µm. (D) H&E-
stained tumor section showing pleomorphic cell (arrow); bar = 100 µm. (E) Desmin staining of leg tumor
showing neoplastic cells (NC) and muscle ﬁbers (MF); bar = 500 µm. (F) Desmin staining of neoplastic cells;
bar = 50 µm.results reported here are part of a larger study
that also investigated the health effect of
embedded DU fragments. We did not observe
tumor formation in the DU-implanted rats
(Kalinich JF, Miller AC, McClain DE,
unpublished data).
Upon euthanasia, the animals underwent
necropsy, and tissue samples were taken for
various analyses. Figure 2 shows the appear-
ance of the hind limb of rats implanted with
Ta (Figure 2A) or WA (Figure 2C) for 26 and
23 weeks, respectively, before surgical removal
of the implanted pellets. The gross anatomy of
the Ta-implanted leg is normal, whereas in the
WA leg the tumor is clearly visible. Upon dis-
section, no obvious abnormalities were
observed in the Ta-implanted animals, and the
pellets could be easily removed (Figure 2B).
However, in the WA-implanted animals, the
pellets were surrounded by tumor (Figure 2D).
In many cases, the interior of the tumor had
become necrotic and/or hemorrhagic. Similar
tumors were found for both WA- and Ni-
implanted animals. In low-dose WA animals,
tumors were found surrounding the WA pel-
lets only. No tumors were found surrounding
implanted Ta pellets. Implanted WA pellets
rapidly oxidized and had a slightly eroded
appearance. Ta pellets did not have an eroded
appearance even after implantation for
6 months. However, despite their appearance,
the WA pellets lost < 5% of their mass over
this time.
Tumor tissue was histopathologically
examined and characterized. Figure 3A shows
the neoplastic cells surrounding the site of the
implanted WA pellet. These cells infiltrated
preexisting skeletal muscle ﬁbers. Fibers that
became isolated by this process degenerated
and demonstrated a loss of cross-striations
and internalization of nuclei (Figure 3B,C).
Neoplastic cells were pleomorphic with
marked anisocytosis and anisokaryosis
(Figure 3D). In addition, an extremely high
mitotic rate was observed in these cells, and
bizarre mitoses were present. Immunohisto-
chemical staining was used to determine the
origin of these neoplastic cells. The cells were
strongly positive for desmin (Figure 3E,F),
suggesting a skeletal muscle origin.
In the WA-implanted animals, the tumors
had metastasized to the lung. None of the Ni-
implanted animals showed signs of lung
metastases, although some exhibited endoge-
nous histiocytic lipid pneumonia not seen in
the WA animals. Figure 4A shows numerous
metastatic foci in the lungs of a high-dose
WA rat. These multiple masses obscure
> 50% of the lung surface and up to 90% in
the latter stages of development. Figure 4B
shows a photomicrograph of these pulmonary
metastases. Apparent is the multifocal, vascu-
lar orientation of these neoplasms. There are
neoplastic cells surrounding the arterioles and
bronchioles, expanding the alveolar septae,
and replacing alveolar spaces. These neo-
plastic cells have a high mitotic rate and are
often seen surrounding or occluding arterioles
(Figure 4C). Figure 4D shows that the
metastatic neoplastic cells, as well as vascular
and airway smooth muscle, are strongly posi-
tive for the muscle marker desmin.
Selected hematologic and organ weight
parameters for euthanized rats are shown in
Table 1. The Ta data were obtained from rats
implanted with Ta pellets for 6 months. The
data for the remaining groups were obtained
at the time the rats became moribund because
of tumor development. No signiﬁcant differ-
ences in organ/body weight ratios were seen
for the low-dose WA- or Ni-implanted ani-
mals compared with Ta-implanted control
rats. However, high-dose WA-implanted rats
showed signiﬁcantly higher spleen:body weight
ratios compared with control rats. In addition,
thymus:body weight ratios were decreased in
the high-dose WA rats. Because the spleen and
thymus are integral components of the immune
system, these changes suggest that embedded
WA, at certain levels, may be immunotoxic.
The kidney:body weight ratio for high-dose
WA rats was also signiﬁcantly higher than that
of Ta-implanted rats. High-dose WA rats euth-
anized 1 and 3 months after pellet implantation
also exhibited signiﬁcantly elevated spleen:body
weight ratios compared with the appropriate
Ta-implanted control rats (Tables 2 and 3).
Thymus:body weight ratios, however, were not
significantly different. At 3 months post-
implantation, the kidney:body weight ratio in
high-dose WA rats was signiﬁcantly higher than
that in Ta rats, but it was signiﬁcantly lower
at 1 month postimplantation. There were no
1- and 3-month Ni-implanted groups.
WA-implanted animals had significant
changes in a number of hematologic parame-
ters. Rats implanted with 20 WA pellets
exhibited signiﬁcant increases in white blood
cell counts, red blood cell counts, hemoglobin,
and hematocrit levels compared with Ta con-
trol rats, whereas rats implanted with 20 Ni
pellets had signiﬁcant decreases in red blood
cell counts, hemoglobin, and hematocrit lev-
els (Table 1). Hematologic parameters from
low-dose WA rats were not statistically differ-
ent from controls. Statistically significant
increases in red blood counts, hemoglobin,
and hematocrit levels were observed in high-
dose WA animals as early as 1 month after
pellet implantation and persisted throughout
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Figure 4. Lung metastases from WA-implanted F344 rats. (A) Gross appearance of pulmonary metastases
from WA-implanted rat (arrows indicate metastatic foci); bar = 1 cm. (B) H&E-stained section of pulmonary
metastases (arrows); bar = 1 mm. (C) H&E-stained section of an occluded pulmonary arteriole [arrow indi-
cates vascular smooth muscle wall (AW)] showing neoplastic cells with numerous mitoses (arrows); bar =
50 µm. (D) Desmin staining of pulmonary metastases (arrows); bar = 500 µm.the experimental period (Tables 2 and 3). In
addition, there were statistically significant
increases in the numbers of neutrophils,
lymphocytes, monocytes, and eosinophils pre-
sent in high-dose WA animals. Low-dose WA
animals had elevated neutrophil, lymphocyte,
and monocyte numbers at 3 months post-
implantation, but only the neutrophil numbers
were statistically different from the controls at
the 5–6 month euthanasia point. The Ni-
implanted animals had signiﬁcantly lower lym-
phocyte counts than the controls. All other
parameters were statistically identical to the
controls. These results suggest there is a dose-
dependent perturbation in many hematology
parameters as a result of an increasing WA
pellet number.
Discussion
Tungsten-based alloys are currently being used
as replacements for DU in kinetic-energy pen-
etrators and for lead in small-caliber ammuni-
tion. However, the health effects of these
unique alloys have not been investigated,
especially in the case of embedded fragments
such as shrapnel wounds. In this study, using
male F344 rats and a system designed to inves-
tigate the effects of embedded metal fragments
(AFRRI 1996), we have shown the embedded
weapons-grade WA (91.1% W, 6.0% Ni,
2.9% Co) results in rapid tumor formation at
the implantation site in 100% of the rats. The
rate of tumor formation correlates with pellet
number. Ni-implanted rats also develop
tumors at the implantation site, although not
as rapidly as seen with WA. Histopathologic
and immunohistochemical data support a
diagnosis of a pleomorphic rhabdomyo-
sarcoma for both the WA- and Ni-induced leg
tumors (Altmannsberger et al. 1985).
Rats implanted with 20 WA pellets (high-
dose WA) showed significantly increased
spleen:body weight ratios compared with Ta
control rats. Low-dose WA rats (four WA pel-
lets) also exhibited increased spleen:body
weight ratios, but these increases were not sta-
tistically significant (ANOVA followed by
Dunnett’s test). Values for Ni-implanted rats
were identical to control rats. The spleen
changes observed in the high-dose WA rats
were apparent as early as 1 month after pellet
implantation. Once again, low-dose WA rats
showed increased, but not statistically signiﬁ-
cant, spleen:body weight ratios. With the
exception of the spleen, the only other
organ:body weight perturbations were seen in
high-dose WA rats and included a decrease in
thymus:body weight ratio at approximately
5 months and changes in kidney:body weight
ratios. The 1-month kidney:body weight ratio
for high-dose WA rats was signiﬁcantly lower
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Table 1. Selected hematologic and organ weight parameters (mean ± SEM) for euthanized rats.
Ta WA (low) WA (high) Ni
White blood cells (103/µL)  3.19 ± 0.24 3.95 ± 0.43 4.56 ± 0.29* 2.56 ± 0.20
Red blood cells (106/µL)  8.32 ± 0.09  8.03 ± 0.19 10.10 ± 0.07**  7.46 ± 0.13**
Hemoglobin (g/dL) 14.50 ± 0.13  13.90 ± 0.36  16.46 ± 0.30**  12.95 ± 0.23**
Hematocrit (%)  41.77 ± 0.53  40.38 ± 0.96  50.18 ± 0.39** 38.12 ± 0.77**
MCV (fL) 50.22 ± 0.16 50.26 ± 0.28  49.71 ± 0.16  51.08 ± 0.66
MCH (pg)  17.46 ± 0.15  17.31 ± 0.13  16.30 ± 0.28** 17.35 ± 0.08
MCHC (g/dL)  34.77 ± 0.36  34.46 ± 0.32  32.81 ± 0.62** 34.05 ± 0.50
RDW (%)  12.54 ± 0.09 13.07 ± 0.11** 13.77 ± 0.09** 13.04 ± 0.16*
Platelets (103/µL)  562.00 ± 14.72  542.05 ± 14.27 467.50 ± 17.57**  487.18 ± 26.10*
MPV (fL)  9.93 ± 0.69  8.64 ± 0.52  10.13 ± 0.62 8.97 ± 0.52
Neutrophils (103/µL)  0.79 ± 0.05  1.03 ± 0.09*  1.31 ± 0.12**  0.78 ± 0.09
Lymphocytes (103/µL)  2.21 ± 0.18 2.42 ± 0.17  2.95 ± 0.23*  1.63 ± 0.12*
Monocytes (103/µL)  0.07 ± 0.01  0.09 ± 0.02  0.13 ± 0.02* 0.05 ± 0.01
Eosinophils (103/µL)  0.08 ± 0.01 0.08 ± 0.01  0.12 ± 0.01**  0.06 ± 0.01
Basophils (103/µL) 0.02 ± 0.00 0.03 ± 0.00  0.03 ± 0.00  0.02 ± 0.00
Spleen (mg/g bw) 2.18 ± 0.10  2.30 ± 0.08  2.60 ± 0.06** 2.17 ± 0.05
Thymus (mg/g bw) 0.86 ± 0.03 0.76 ± 0.04 0.70 ± 0.04*  0.74 ± 0.07
Liver (mg/g bw) 29.21 ± 0.28  29.39 ± 0.24  28.77 ± 0.35  29.52 ± 0.39
Kidney (mg/g bw) 5.13 ± 0.06  5.13 ± 0.06  5.36 ± 0.05*  5.15 ± 0.08
Testes (mg/g bw) 7.31 ± 0.07  7.20 ± 0.08  7.40 ± 0.10  7.21 ± 0.14
Abbreviations: bw, body weight; MCH, mean corpuscular hemoglobin; MCHC, mean corpuscular hemoglobin concentra-
tion; MCV, mean corpuscular volume; MPV, mean platelet volume; RDW, red blood cell distribution width. Data represent
mean ± SEM of 20 observations (10 for Ni group).
*p < 0.05, and **p < 0.01 compared with the Ta control group by one-way ANOVA followed by Dunnett’s test for group
mean comparisons.
Table 2. Selected hematologic and organ weight parameters (mean ± SEM) for
rats implanted with metal pellets for 3 months.
Ta  WA (low) WA (high)
White blood cells (103/µL) 2.88 ± 0.20  4.06 ± 0.14** 4.01 ± 0.21**
Red blood cells (106/µL)  7.48 ± 0.06  8.48 ± 0.15*  9.10 ± 0.70**
Hemoglobin (g/dL) 12.90 ± 0.09 15.48 ± 0.35*  17.29 ± 0.15**
Hematocrit (%)  38.10 ± 0.27  42.14 ± 0.73*  44.79 ± 0.62**
MCV (fL) 50.96 ± 0.45  49.70 ± 0.09  48.87 ± 0.39
MCH (pg)  17.26 ± 0.12  18.27 ± 0.17  17.65 ± 0.12
MCHC (g/dL)  33.84 ± 0.35  36.71 ± 0.31**  35.89 ± 0.31**
RDW (%)  12.82 ± 0.33  12.68 ± 0.12  13.61 ± 0.09**
Platelets (103/µL)  513.20 ± 38.36  585.11 ± 35.87  568.29 ± 8.82
MPV (fL) 9.58 ± 1.13  9.14 ± 0.59  11.74 ± 0.51
Neutrophils (103/µL) 0.62 ± 0.04  0.79 ± 0.03*  0.91 ± 0.08* 
Lymphocytes (103/µL) 2.10 ± 0.16  3.06 ± 0.14* 2.82 ± 0.17*
Monocytes (103/µL)  0.04 ± 0.01  0.07 ± 0.01*  0.08 ± 0.01*
Eosinophils (103/µL)  0.09 ± 0.01  0.09 ± 0.01  0.09 ± 0.01
Basophils (103/µL)  0.01 ± 0.00  0.01 ± 0.00 0.02 ± 0.00
Spleen (mg/g bw) 2.07 ± 0.03  2.16 ± 0.03  2.50 ± 0.03**
Thymus (mg/g bw) 0.73 ± 0.03  0.84 ± 0.03  0.70 ± 0.04
Liver (mg/g bw) 30.58 ± 0.33  31.00 ± 0.33  30.27 ± 0.31
Kidney (mg/g bw) 5.43 ± 0.06  5.73 ± 0.23  5.76 ± 0.04**
Testes (mg/g bw) 8.34 ± 0.12  8.21 ± 0.46  8.42 ± 0.18
Abbreviations: bw, body weight; MCH, mean corpuscular hemoglobin; MCHC, mean cor-
puscular hemoglobin concentration; MCV, mean corpuscular volume; MPV, mean
platelet volume; RDW, red blood cell distribution width. Data represent mean ± SEM of
15 observations.
*p < 0.05, and **p < 0.01 compared with the age-matched Ta control group by one-way
ANOVA followed by Dunnett’s test for group mean comparisons.
Table 3. Selected hematologic and organ weight parameters (mean ± SEM) for
rats implanted with metal pellets for 1 month.
Ta  WA (low) WA (high)
White blood cells (103/µL) 3.86 ± 0.20  3.81 ± 0.14  3.86 ± 0.21
Red blood cells (106/µL)  7.84 ± 0.08  7.74 ± 0.07  8.50 ± 0.07**
Hemoglobin (g/dL) 13.65 ± 0.15  14.81 ± 0.16  15.84 ± 0.14**
Hematocrit (%)  40.15 ± 0.42  39.66 ± 0.50  43.29 ± 0.35**
MCV (fL) 51.20 ± 0.14  51.22 ± 0.31  50.98 ± 0.19
MCH (pg)  17.41 ± 0.05  19.12 ± 0.09  18.64 ± 0.19**
MCHC (g/dL)  34.01 ± 0.12  37.37 ± 0.29  36.56 ± 0.41**
RDW (%)  12.21 ± 0.11  12.69 ± 0.11  14.18 ± 0.18**
Platelets (103/µL)  646.50 ± 18.76  641.00 ± 17.97  756.20 ± 43.48*
MPV (fL) 7.91 ± 0.40  8.56 ± 0.39  9.90 ± 0.55*
Neutrophils (103/µL) 0.65 ± 0.04  0.79 ± 0.05  0.81 ± 0.04** 
Lymphocytes (103/µL) 3.04 ± 0.18  2.85 ± 0.13  2.90 ± 0.18
Monocytes (103/µL)  0.06 ± 0.00  0.06 ± 0.01  0.07 ± 0.00
Eosinophils (103/µL)  0.07 ± 0.01  0.08 ± 0.01  0.05 ± 0.00*
Basophils (103/µL)  0.02 ± 0.00  0.02 ± 0.00  0.01 ± 0.00
Spleen (mg/g bw) 2.37 ± 0.06  2.42 ± 0.05  2.73 ± 0.04**
Thymus (mg/g bw)  1.07 ± 0.03  1.14 ± 0.04  1.06 ± 0.03
Liver ((mg/g bw) 34.47 ± 0.26  34.31 ± 0.22  34.18 ± 0.61
Kidney (mg/g bw) 6.17 ± 0.08  6.06 ± 0.06  5.91 ± 0.05*
Testes (mg/g bw) 10.10 ± 0.16  9.86 ± 0.13  9.98 ± 0.11
Abbreviations: bw, body weight; MCH, mean corpuscular hemoglobin; MCHC, mean cor-
puscular hemoglobin concentration; MCV, mean corpuscular volume; MPV, mean
platelet volume; RDW, red blood cell distribution width. Data represent mean ± SEM of 15
observations.
*p < 0.05, and **p < 0.01 compared with the age-matched Ta control group by one-way
ANOVA followed by Dunnett’s test for group mean comparisons.than control. However, from 3 months on,
these ratios were signiﬁcantly higher than con-
trol. It is possible that the lower kidney weights
at 1 month postimplantation represent a toxic
response to the heavy metals from the
implanted pellets, but by 3 months and later,
the kidney has begun to respond in a different
manner. Although there were no gross abnor-
malities of the kidney at necropsy, we continue
to investigate this observation.
A variety of hematologic changes were
observed in WA- and Ni-implanted rats. Ni-
implanted rats showed a signiﬁcant decrease in
red blood cells, hemoglobin, and hematocrit at
the time of morbidity, indicating possible Ni-
induced anemia. For low-dose WA rats the
hematologic changes, including significant
increases in red blood cells, white blood cells,
hemoglobin, hematocrit, neutrophils, lympho-
cytes, and monocytes, peaked at 3 months
postimplantation and returned to normal by
5–6 months. High-dose WA rats demonstrated
the same changes observed in low-dose WA
rats, but they occurred much more rapidly (as
early as 1 month postimplantation) and per-
sisted throughout the life of the animal. The
splenomegaly and hematologic changes
observed in these rats are suggestive of poly-
cythemia. Cobalt has been used experimentally
to induce polycythemia in rats (Endoh et al.
2000; Rakusan et  al. 2001), although the con-
centration required is far greater than found in
the WA pellets. In addition, the speed at which
these hematologic changes occurred in the
high-dose WA rats was also surprising. These
results suggest a dose-dependent perturbation
in many hematology parameters as a result of
an increasing WA pellet number.
The search for munitions that are consid-
ered environmentally friendly yet still retain
their military effectiveness has led to the appear-
ance of many unique alloys on the modern bat-
tlefield. Often, decisions on the health
consequences of exposure (inhalation, inges-
tion, wound contamination, etc.) to these spe-
ciﬁc alloys are based on studies that investigated
only one speciﬁc metal of the alloy rather than
the particular alloy in question. Tungsten-based
munitions are a recent addition to many coun-
tries’ arsenals, primarily in response to the con-
tinuing concerns regarding the potential
environmental and health effects of DU in
kinetic-energy penetrators and of lead in small-
caliber ammunition. For years, exposure to
tungsten was thought to be of little conse-
quence to health. In fact, tungsten is occasion-
ally found as a minor component in some of
the various alloys used to produce medical
implant devices such as artiﬁcial hips and knees.
The tungsten concentration in these alloys
ranges from 5% to 15%. Because the alloy used
in WA munitions usually contains > 90% tung-
sten, along with smaller amounts of other met-
als, it was also assumed that exposure to these
alloys would present little or no health risk. As
we have shown here, this is not the case in our
rodent model. Embedded WA pellets not only
resulted in aggressive, metastatic, pleomorphic
rhabdomyosarcomas, but also caused signiﬁcant
hematopoietic changes well before the carcino-
genic effect was observed. It seems unlikely that
these adverse health effects can be attributed
solely to the small amounts of Ni and/or Co
present in the alloy. The tumors induced by the
100% Ni implants occurred later than those
induced by the alloys containing 6% Ni.
However, recent in vitro studies have demon-
strated a synergistic effect in terms of damage
when tungsten is present with these metals
(Miller et al. 2001, 2002).
The mechanism of the effects reported here
with embedded WA pellets remains unclear.
Despite the fact that the smooth and imperme-
able surface of the pellets represent characteris-
tics known capable of inducing foreign-body or
solid-state carcinogenesis (Bates and Klein
1966; Brand et al. 1975), this process is
unlikely to have occurred in our experiments
because implanted Ta pellets of an identical
geometry and surface resulted in no tumor for-
mation. One possibility is that free-radical reac-
tions at the interface of the pellet and tissue
could result in damage leading to carcinogene-
sis. Recently, the role of tungsten in human
health and disease has come under increased
scrutiny. Environmental testing of the leukemia
cluster around Fallon, Nevada, in the United
States showed slightly elevated levels of several
heavy metals including uranium and Co but
signiﬁcantly elevated levels of tungsten [Centers
for Disease Control and Prevention (CDC)
2003]. Although no deﬁnitive link between ele-
vated tungsten levels and cancer has been estab-
lished, because of the uncertainty surrounding
this issue, the U.S. National Toxicology
Program recently added tungsten to their list of
compounds to be assessed for adverse health
effects. Further study of the health effect of
tungsten and WAs is clearly indicated.
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